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Abstract
Background: High-risk strains of human papillomavirus (HPV) cause cervical cancer. American Indian (AI) women in
the Northern Plains of the U.S. have significantly higher incidence and mortality rates for cervical cancer than White
women in the same geographical area. We compared HPV prevalence, patterns of HPV types, and infection with
multiple HPV types in AI and White women living in South Dakota, U.S.
Methods: We analyzed the HPV status of cervical samples collected in 2006-2008 from women aged 18-65 years
who attended two rural AI reservation clinics (n = 235) or an urban clinic in the same area serving mostly White
women (n = 246). Data collection occurred before HPV vaccination was available to study participants. HPV DNA
was amplified by using the L1 consensus primer system and an HPV Linear Array detection assay to identify HPV
types. We used chi-square tests to compare HPV variables, with percentages standardized by age and lifetime
number of sexual partners.
Results: Compared to White women, AI women were younger (p = 0.01) and reported more sexual partners (p <
0.001). A lower percentage of AI women tested negative for HPV infection compared to Whites (58% [95% CI = 51-
65] vs. 77% [95% CI = 71-82]; p < 0.001), and a higher percentage of AI women were infected by oncogenic types
(30% [95% CI = 25-36] vs. 16% [95% CI = 11-21]; p = 0.001). Infections among AI women showed a wider variety
and very different pattern of HPV types, including a higher prevalence of mixed HPV infections (19% [95% CI = 26-
38] vs. 7% [95% CI = 4-11]; p = 0.001). AI women had a higher percentage of HPV infections that were not
preventable by HPV vaccination (32% [95% CI = 26-38] vs. 15% [95% CI = 11-21]; p < 0.001).
Conclusions: A higher HPV burden and a different HPV genotyping profile may contribute to the high rate of
cervical cancer among AI women.
Keywords: cervical cancer, Pap screening, HPV genotypes, American Indians, health disparities, human papilloma-
virus, types
Background
Cervical cancer is the second most common cause of
cancer-related deaths in women worldwide [1] and a
leading cause of cancer mortality among American
Indian (AI) women [2,3]. Compared to other U.S. racial
and ethnic groups, AI women experience striking health
disparities in relation to cervical cancer, including a
higher prevalence [4-9], a more rapidly increasing
incidence [10,11], and poorer survival [12,13]. The
Aberdeen Area Indian Health Service, which encom-
passes 16 different tribes located in South Dakota,
North Dakota, Nebraska, and Iowa, reported an age-
adjusted cervical cancer mortality rate of 4.3/100,000
from 1996 to 1998 [14], almost twice the rate reported
in the general U.S. population [15]. Our previous work
found a high prevalence of human papillomavirus
(HPV) infection among AI women residing on reserva-
tions in the same geographic region, and suggested that
types other than HPV-16 and HPV-18 comprised a
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In a recent study of more than 9,600 U.S. women, the
overall prevalence of high-risk HPV types among AI and
Alaska Native women (representing 2% of the total sam-
ple) was 25% [17], which is substantially higher than the
general U.S. population prevalence of 15% [18].
Infection with HPV, especially HPV-16 and HPV-18,
is the most common cause of cervical cancer [19]. Pre-
venting HPV infection is critical to public health efforts
to reduce precancerous lesions and cervical cancer inci-
dence and mortality. In 2007, the U.S. Food and Drug
Administration approved the first vaccine to prevent
infection by the most common oncogenic HPV types
present in the general U.S. population; a second HPV
vaccine was approved in 2009. Despite striking cervical
cancer disparities, little is known about patterns of HPV
infection in AI communities that can inform the ade-
quacy of prevention provided for AI women by existing
HPV vaccines. We therefore examined women seen in
two rural AI reservation clinics and one urban clinic
serving primarily White women in the Northern Plains.
Our aims were to 1) compare HPV prevalence and pat-
terns between the AI and White clinic samples, and 2)
compare proportions of women in each group who were
infected by HPV types that can be prevented by existing
vaccines.
Methods
Setting
This study was conducted in two AI reservation clinics
in South Dakota operated by the Indian Health Service,
and in one urban clinic serving primarily White women
located in Sioux Falls, South Dakota. The Indian Health
Service is an agency of the U.S. Department of Health
and Human Services that provides healthcare to AIs and
Alaska Natives. Both reservation sites are large, rural,
and extremely economically disadvantaged. According to
2004 data, 38,000 tribal members were living within
reservation boundaries at Site 1, and in fiscal year 2002,
4,406 women between the ages of 15 and 64 received
services at the Indian Health Service unit at this site
[20]. Site 2 had 21,245 tribal members living within
reservation boundaries in 2004 [21], and in fiscal year
2002, 3,100 women between the ages of 15 and 64
received services at the Indian Health Service unit at
this site. Of note, the high school dropout rate in Site 1
is over 70%, and the teacher turnover rate is 800% that
of the U.S. national average [22]. In contrast, in Site 2,
the tribe implemented a program that increased gradua-
tion rates from 48% to 72% at the main public high
school [23].
The urban site in Sioux Falls is a multi-specialty
obstetrics and gynecology clinic serving South Dakota
and parts of Minnesota, Iowa, and Nebraska, with
approximately 30,000 outpatient visits annually. In 2003,
the population of Sioux Falls was 133,834, and only 6%
of residents lived below the poverty line [24]. The urban
population is predominantly White (92%), with small
numbers of Latino (2%), African American (2%), Asian
(1%), and AI (2%) residents [25]. Only 5% of adults lack
a high school education or equivalent [26].
Of note, 99% of women attending the two reservation
clinics self-identified as AI and 96% of women from the
urban clinic self-identified as White. Hereafter, we refer
to the rural sample (Site 1 and Site 2) as AI and the
urban sample as White.
Before enrollment, all women signed an informed con-
sent form to participate in this study. Both this project
and the associated consent forms were approved by the
institutional review boards of the University of South
Dakota and the University of Washington, as well as by
the Aberdeen Area Tribal Review Board and the indivi-
dual participating tribes. Tribal approval included review
by the tribal Health and Human Service Committees
and formal resolutions from the tribal councils.
Participants
Potential candidates for this study included all sexually
active women with an intact uterus, aged 18-65 years,
who presented for annual gynecologic examinations or
other non-malignancy related reasons. Data collection
for all White women took place before the Gardasil vac-
cine was approved in 2007, so that no White partici-
pants had prior HPV vaccination. Data collection for AI
women took place over a longer time frame because of
recruitment issues, so that some AI participants were
sampled after vaccine approval. However, the Indian
Health Service did not pay for HPV vaccination during
this time period, and the women recruited for our study
were older than the age range initially targeted for the
vaccine (11-12 years) [27], so we are confident that no
AI participants had prior HPV vaccination.
Two of the authors trained all clinic staff and provi-
ders. Training consisted of a formal explanation of the
project and the procedures for collecting and handling
study samples, followed by direct observation of interac-
tions with patients. Given budget constraints, clinical
commitments, and other assignments, study staff were
not always available at clinic sites to enroll patients.
When present in the clinics, study staff reviewed
patients’ charts to assess eligibility, and eligible women
were then invited by participating physicians to enroll in
the study. Pregnant women were included if their enrol-
ling physicians noted no health risk or contraindication,
such as preterm labor or vaginal bleeding. In most
cases, a Pap test was obtained first, followed by cervical
sampling and completion of surveys. Surveys were admi-
nistered by a trained staff member in a private setting.
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All HPV genotypes that cause cervical cancer belong to
the Alpha genus. These include HPV-51 (Alpha 5);
HPV-56 and HPV-66 (Alpha 6); HPV-18, HPV-39,
HPV-45, and HPV-59 (Alpha 7); and HPV-16, HPV-31,
HPV-33, HPV-35, HPV-52, and HPV-58 (Alpha 9)
[28,29]. Of note, the Alpha 7 and Alpha 9 types are
most frequently implicated in cervical cancer cases
worldwide, although all types in the Alpha genus have
been implicated.
HPV Vaccines
Two HPV vaccines have been approved in the U.S. The
first, Gardasil, was approved in 2007 and prevents infec-
tion by HPV types 6, 11, 16, and 18. The second, Cer-
varix, was approved in 2009 and prevents infection by
HPV types 16 and 18, with prescription information cit-
ing a post hoc analysis that showed efficacy against
HPV-31 related CIN 2+ lesions. Our analysis focused
only on the four HPV types prevented by Gardasil.
Because of scientific uncertainty, we did not consider
any potential HPV protection through the reported
“cross protection” phenomenon [30].
Sample Collection and Assay Methods
The study was conducted between December 2006 and
November 2008. At each site, four to seven providers
collected study samples. Cervical swabs were collected
from the cervix under visualization. Each cervical sample
was immediately chilled on ice and later cataloged and
frozen at -80° C. Samples from the urban clinic were
collected daily and taken to the study laboratory. Sam-
ples from the two Indian Health Service units were
batch-shipped on ice overnight to the same laboratory.
After all samples were collected, they were processed by
the same technician, and HPV analysis was conducted
under the same laboratory conditions with HPV test kits
bearing the same lot number.
After the DNA samples were defrosted, a digestion
solution was added to 1.0 ml of sample to achieve a
concentration of 200 micrograms of proteinase K and
0.1% laureth-12, then incubated for 1 hour at 56° C.
DNA was precipitated from a 150 microliters aliquot
of digested material overnight at -20° C in 1.0 ml of
absolute ethanol containing 75 microliters of 5.0 M
ammonia acetate. After the precipitated DNA was cen-
trifuged at 13,000 g for 30 minutes, supernatant was
aspirated and the remaining DNA was dried overnight
at room temperature. The pellet was resuspended in
2 0m i c r o l i t e r so f1 0m MT r i sa n d1m ME D T A ,t h e n
incubated for 15 minutes at 95° C. The integrity of the
extracted DNA was confirmed by a standard 1% agar-
ose gel electrophoresis followed by staining with ethi-
dium bromide.
The DNA extracts were stored at -80° C until amplifi-
cation by PCR using the L1 consensus primer system
and processed for HPV genotyping as described in a
previous study [16]. Briefly, 20 microliters of PCR pro-
duct were separated on a 2% agarose gel to confirm
amplification of internal controls (Β-globin) and the
HPV L1 gene. HPV genotyping strips (Roche Diagnos-
tics, Indianapolis, IN) were used to detect 37 high- and
low-risk HPV genotypes, including high-risk genotypes
that could progress to cervical cancer. Non-oncogenic
HPV genotypes included 6, 11, 26, 40, 42, 53, 54, 55, 61,
62, 64, 69, 71, 72, 81, 82, 83, 84, IS39, and CP6108.
Oncogenic or probably oncogenic HPV genotypes
included 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66,
67, 68, 70, and 73. Reactions were amplified with a
Biorad system according to published instructions.
Seventy-five microliters of denatured, biotinylated ampli-
fied product were placed with genotyping strips into
individual wells of the typing trays and covered with
hybridization buffer. After HPV DNA detection, indivi-
dual strips were rinsed in deionized water and stored in
citrate buffer. Interpretation was based on a labeled
acetate overlay with lines indicating the position of each
probe relative to a reference mark on the strip denoting
high- and low-risk types. Two independent investigators
interpreted the data, with discrepancies resolved by a
third investigator.
Measures
We categorized age in years (18-24, 25-34, 35-44, 45-54,
55-65) and lifetime number of sexual partners (1, 2-3, 4-
5, 6-9, ≥10), after checking to ensure that the categor-
ized variables performed as well as the continuous vari-
ables in the statistical analysis. We chose this approach
to simplify presentation of standardized descriptive sta-
tistics, and to allow for easier modeling of potential
non-linear associations between age and HPV infection.
We defined infection status as not infected, infected by
a single HPV type, or infected by multiple HPV types.
We measured oncogenic infection with three separate
and independent variables indicating Alpha 7 infection
(oncogenic HPV types 16, 31, 33, 35, 52, 58, or 67),
Alpha 9 infection (oncogenic HPV types 18, 39, 45, 59,
68, or 70), and infection by oncogenic HPV types not
classified as Alpha 7 or Alpha 9 (HPV types 51, 56, 66,
73, or 82). Based on this information we created a global
variable indicating infection by at least one oncogenic
HPV type.
We used two sets of variables to compare each
woman’s HPV infection profile to the four HPV types
prevented by the Gardasil vaccine (types 6, 11, 16, and
18). First, we created four binary indicators of infection
by each of the four types. Next, we created a single
composite variable to represent hypothetical protection
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which each woman received vaccination before HPV
exposure. This variable comprised four mutually exclu-
sive categories, defined as 1) not infected by any HPV
type, 2) no prevention (infected only by HPV types not
prevented by the vaccine), 3) partial prevention
(infected by at least one of HPV types 6, 11, 16, or 18
and at least one other HPV type not prevented by the
vaccine), or 4) full prevention (infected only by HPV
types 6, 11, 16, or 18).
Statistical Analysis
Preliminary data analyses indicated that the two AI
groups were sufficiently similar in relation to all study
variables to combine them into a single sample for this
analysis. To examine our first study aim, we calculated
percentages to describe the distribution of age, lifetime
number of sexual partners, HPV infection status, and
oncogenic infection measures separately by clinic popu-
lation (reservation vs. urban), with the chi-square test to
compare the distributions. We anticipated that age and
number of sexual partners, which are known risk factors
for HPV infection, might be differently distributed
between AI and White participants. Therefore, we
adjusted HPV infection status and oncogenic infection
percentages for these variables by using direct standardi-
zation, and we present them with 95% confidence inter-
vals (CI). We also calculated the prevalence of each
HPV infection status category by age group, using a
non-parametric test for trend to evaluate the correlation
of age and any HPV infection separately for each clinic
population. To visually represent HPV prevalence pat-
terns, we created a bar chart showing the percentage of
patients from each clinic population who tested positive
for each of 36 different HPV types.
For our second study aim, we calculated the percen-
tage of women who were infected by each of the four
HPV types (6, 11, 16, and 18) that are prevented by
Gardasil. We calculated percentages to compare the dis-
tribution of hypothetical vaccine prevention (not
infected, infection not prevented by the vaccine, infec-
tion partially prevented by the vaccine, infection com-
pletely prevented by the vaccine) by clinic population.
All percentage values were adjusted for age and number
of sexual partners, and are presented with 95% CI, with
the chi-square test to compare distributions between the
two populations.
All analyses were performed by using Stata version 10
[31]. For chi-square tests, we considered an alpha of
0.05 as the threshold for statistical significance.
Results
We collected cervical samples from 258 AI women (104
and 154 women at Sites 1 and 2, respectively) and from
252 White women at the urban clinic. Participation
rates exceeded 90%, with the total number of refusals
ranging from four to seven among the three clinic sites.
Some faint positive HPV results required adjudication
by a third reader, but all positive results were typable.
After excluding three women with missing data for HPV
status and 26 women with missing data for age or num-
ber of sexual partners, data on 481 women (AI n =2 3 5 ,
White n = 246) were available for analysis. The vast
majority of study participants were recruited during
annual gynecological examinations. All participants had
health insurance of some kind. For AI women, health-
care was provided and paid for by the Indian Health
Service; the White women were covered by private or
government-sponsored insurance (e.g., Medicaid).
As shown in Table 1, AI women were typically
younger (p = 0.01) and reported a higher lifetime num-
ber of sexual partners (p < 0.001) than their White
counterparts.
Table 1 Distribution of risk factors and HPV prevalence
by clinic site
American
Indian
White
(n = 235) (n = 246)
Risk factors % % Χ
2 p-
value
Age, years
18 - 24 26 13 0.01
25 - 34 31 33
35 - 44 25 29
45 - 54 12 18
55 - 65 6 8
Sexual partners
1 7 23 < 0.001
2-3 2 4 2 9
4-5 1 2 1 2
6-9 3 3 2 4
≥ 10 24 12
HPV prevalence
a % (95% CI) % (95%
CI)
Χ
2p-
value
Infection status
Not infected 58 (51-65) 77 (71-82) < 0.001
Infected by single HPV
type
23 (18-30) 16 (12-21)
Infected by multiple HPV
types
19 (15-24) 7 (4-11)
Alpha 7 oncogenic infection
b 12 (9-16) 8 (5-13) 0.03
Alpha 9 oncogenic infection
c 18 (13-24) 9 (6-14) < 0.001
Other oncogenic infection
d 8 (5-11) 2 (1-4) 0.001
Any oncogenic infection 30 (25-36) 16 (11-21) < 0.001
a Prevalence estimates are standardized by age and number of sexual
partners;
b HPV types 16, 31, 33, 35, 52, 58, and 67;
c HPV types 18, 39, 45, 59,
68, and 70;
d HPV types 51, 56, 66, 73, 82.
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women tested positive for HPV. After standardization
for age and number of sexual partners, prevalent HPV
infection status differed between the two groups (p <
0.001). Overall HPV infection estimates were 42% for AI
women and 23% for White women, with prevalence of
multiple HPV infection nearly three times higher in AI
women than in White women (19% vs. 7%). AI women
also had higher standardized prevalence estimates for
infection by Alpha 7, Alpha 9, and other oncogenic
types, as well as nearly double the prevalence of infec-
tion by any oncogenic HPV type, compared to White
women (30% vs. 16%, p < 0.001). In addition, AI and
White women exhibited different distributions of HPV
infection across age categories (Table 2). Among AI
women, prevalent infection decreased from the youngest
to the oldest age groups (ptrend < 0.001), whereas no age
trend was evident among White women (ptrend = 0.23).
Figure 1 displays the prevalence for each of 36 HPV
types. Overall, AI women exhibited a wider variety of
HPV infections, with seven HPV types detected only in
AI women. In contrast, White women showed less var-
iation in prevalent infections, with just one HPV type
detected only in White women.
Table 3 shows the percentages of women infected
with each of the HPV types prevented by the Gardasil
vaccine, standardized for age and number of sexual part-
ners. There was no statistically significant difference in
the percentages of women infected by HPV types 6 or
16, but significantly more AI women were infected by
HPV-11 (p =0 . 0 3 )a n dH P V - 1 8( p = 0.02). The two
clinic populations differed significantly with regard to
the prevalence of infections by HPV types that are not
prevented by Gardasil (p < 0.001). The AI group had a
strikingly higher percentage of women with HPV infec-
tions that would not have been prevented at all by the
vaccine (32% vs. 15%), and a higher percentage of
women with infections that would have been only par-
tially prevented by the vaccine (5% vs. 2%).
Discussion
The primary aims of this study were to examine the
prevalence of HPV infection and the distribution of
HPV genotypes, as well as the potential benefit of HPV
vaccination, in two distinct South Dakota populations.
We found that the prevalence of HPV infection among
AI women was more than twice that of White women
in our samples. Because we are extremely confident that
none of the study participants had prior Gardasil vacci-
nation, these differences cannot be attributed, even in
part, to discrepancies in vaccine administration or
uptake. Increasing age was negatively correlated with
HPV infection among AI women, whereas no such
trend was detected among the White sample. These
findings suggest that efforts to prevent HPV infection
must be tailored to the disease burden, the specific HPV
prevalence patterns, and the educational and social
background of the target community.
We previously reported that 22% of AI women in a
Northern Plains service unit had HPV infections, a pre-
valence considerably higher than the 7% observed
among AI women in New Mexico [4] and comparable
to the 21% documented for Alaska Native women [5].
In a recent study of a large and diverse population of U.
S. women, Datta and colleagues reported the prevalence
of high-risk HPV infection among AI and Alaska Native
women as 25% [17]. High-risk types were determined by
the Hybrid Capture 2 assay (Digene, Gaithersburg, MD),
which returns a positive result in the presence of any of
13 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, or 68). Unlike the present study, however,
Datta and colleagues did not identify individual HPV
types, and their sample included fewer than 180 AI
women recruited nationwide.
The disparity in HPV prevalence between AI and
White women residing in the Northern Plains may con-
tribute to the disproportionately high rate of cervical
cancer in the AI population. The Northern Plains inci-
dence rate for cervical cancer in AI women is 11.3 per
100,000, which is 1.5 times higher than in non-Hispanic
White women (7.5 per 100,000). Recent publications
have documented an incidence of cervical cancer among
AI women in South Dakota as high as 16.2/100,000,
Table 2 Prevalence of single and multiple HPV infection
by age category for American Indian and White women
Infection Status
None Single HPV
Type
Multiple HPV
Types
American Indian
a % (95% CI) % (95% CI) % (95% CI)
Age, years
18 - 24 28 (18-40) 31 (21-44) 41 (29-54)
25 - 34 48 (37-59) 33 (23-45) 19 (12-30)
35 - 44 69 (56-80) 19 (11-31) 12 (6-23)
45 - 54 69 (50-83) 14 (5-32) 17 (7-36)
55 - 65 71 (44-89) 14 (4-43) 14 (4-43)
White
b % (95% CI) % (95% CI) % (95% CI)
Age, years
18 - 24 75 (57-87) 9 (3-25) 16 (7-33)
25 - 34 73 (63-82) 16 (9-26) 11 (6-20)
35 - 44 79 (67-87) 16 (9-26) 6 (2-14)
45 - 54 77 (62-87) 21 (11-34) 2 (0-15)
55 - 65 90 (66-97) 11 (3-34) 0 –
Results are unstandardized and presented as prevalence estimates with 95%
CIs.
a Any HPV infection non-parametric test for trend p < 0.001
b Any HPV infection non-parametric test for trend p = 0.29
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women [9], and an age-adjusted cervical cancer mortal-
ity in the Dakotas nearly twice the national average (4.5
per 100,000 vs. 2.7 per 100,000) [8].
We also observed different patterns of HPV infection
in our two study populations. Overall, AI women
showed more variation in prevalent HPV types, and sig-
nificantly more AI women were infected by HPV types
that would not have been prevented by current HPV
vaccines. Previous genotyping studies conducted in pre-
dominantly White populations have documented that
HPV-16 and HPV-18 are implicated in up to 70% of
cervical cancer cases in the U.S and worldwide [32,33],
but virtually no AI women participated in these studies.
Although vaccination is still in order, our results suggest
that the protective benefit conferred by current HPV
vaccines might be less for some AI women than for
their White counterparts. Of note, recent evidence sug-
gests that despite receiving HPV vaccination, some
women still develop cervical cancer, likely unrelated to
HPV-16 or HPV-18 [34]. Among AI women in the pre-
sent study, the diversity of oncogenic types that are not
preventable by existing vaccines might further contri-
bute to the high rates of cervical cancer previously
observed among AI women in the Northern Plains.
Our findings have substantial relevance to public
health efforts aimed at improving cervical cancer screen-
ing among AI women. The “All Women Count” cancer
screening program funded by the State of South Dakota
covers Pap testing for eligible women under the age of
Figure 1 Unstandardized prevalence of each HPV type among American Indian and White women in South Dakota.
Table 3 Prevalence of HPV types prevented by the Gardasil HPV vaccine and hypothetical vaccine protection against
prevalent infections
a
American Indian White
(n = 235) (n = 246)
% (95% CI) % (95% CI)
Infected by HPV types prevented by Gardasil vaccine
Type 6 1 (0-3) 1 (0-2)
Type 11 1 (1-3) 0 –
Type 16 5 (3-8) 6 (3-10)
Type 18 5 (3-10) 1 (1-3)
Hypothetical protection
a by Gardasil against prevalent HPV infection
Not applicable (no infection) 58 (51-65) 77 (71-82)
No protection 32 (26-38) 15 (11-21)
Partial protection 5 (3-8) 2 (1-4)
Full protection 5 (3-10) 6 (3-10)
Prevalence estimates are standardized by age and lifetime number of sexual partners.
a Presumed protection against infection, assuming a counterfactual scenario in which each woman had been vaccinated before HPV exposure.
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cal dysplasia [35]. Notably, the National Breast and Cer-
vical Cancer Early Detection Program found that AI
women more often reported never having a Pap test
than their non-AI counterparts, and also had the highest
proportion (4.4%) of abnormal Pap tests [36]. Although
our findings need to be replicated in other AI commu-
nities, they raise the question of whether the Indian
Health Service might consider universal HPV screening
for selected service units.
This study is limited in several ways. First, because the
study population was a convenience sample drawn from
the local service units, our findings may not be pertinent
to all AI women living in the Northern Plains of the U.
S., and cannot be generalized to other rural or urban
populations. Nevertheless, we had an exceptionally high
participation rate, and we believe that our samples are
an accurate representation of the patient populations,
both AI and White, at all clinic sites. Of note, we have
additional, unpublished results from 212 AI women liv-
ing in Montana (ages 16-65), suggesting an HPV preva-
lence of 37%, very similar to the 42% prevalence
observed in our sample of AIs living in South Dakota.
Second, our sample size was relatively small compared
to many studies of HPV prevalence. Even so, this is the
first study to examine HPV prevalence patterns in a
high-risk AI population with a geographically localized
White comparison group, and despite the small sample
size, we were able to detect statistically significant differ-
ences between the groups, with important clinical and
public health implications.
Third, we cannot disentangle the effects of urban resi-
dence from race. However, very few White women live
on reservations, and only a negligible proportion of AI
women were evaluated in the regionally-matched urban
clinic, making the selection of samples evenly distribu-
ted between race and region virtually impossible.
Fourth, we did not use prior receipt of Gardasil vacci-
nation as an exclusion criterion. Nevertheless, we are
confident that our results remain unaffected by this lim-
itation, since data on all White women and many AI
women were collected before vaccine approval. Further,
the AI women who were sampled in 2007-2008 were
older than the target age range for HPV vaccination and
had no insurance coverage from the Indian Health Ser-
vice for this purpose. Even in the unlikely event that a
few AI participants had prior vaccination, we would
expect any resulting bias to be in the direction of less
prevalent infection in this group.
Fifth, the absence of HPV vaccination among study
participants prevented us from considering population
differences in vaccine uptake; future research should
examine this phenomenon more closely in minority
communities.
Finally, we did not consider the additional prevention
of HPV-31 provided by the Cervarix vaccine. Neverthe-
less, only four AI women, and no White women, were
infected by HPV-31, so the inclusion of Cervarix in this
analysis would have added confusion without altering
our conclusions.
Conclusions
This is the first study of HPV genotyping in a commu-
nity-based sample of AI and White women. Our results
suggest the existence of substantial differences in HPV
prevalence and infection patterns among AI and White
populations, highlighting the need for research on HPV
in high-risk minority groups. If confirmed by future stu-
dies, our results might help to explain the documented
cervical cancer disparities experienced by AI women. As
it is, our findings underscore the need to evaluate vac-
cine efficacy in this population.
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